{"id":474001,"date":"2021-04-08T21:03:21","date_gmt":"2021-04-09T01:03:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=474001"},"modified":"2021-04-08T21:03:21","modified_gmt":"2021-04-09T01:03:21","slug":"fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/","title":{"rendered":"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm"},"content":{"rendered":"

<\/p>\n

FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm<\/b><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–
\nBragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our investigation concerns whether FibroGen has violated the federal securities laws and\/or engaged in other unlawful business practices.\n<\/p>\n

\nClick here<\/a> to participate in the action.\n<\/p>\n

\nOn April 6, 2021, FibroGen issued a statement \u201cprovid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (\u2018CKD\u2019).\u201d Specifically, the Company stated that the safety analyses \u201cincluded post-hoc changes to the stratification factors.\u201d FibroGen further revealed that, based on analyses using the pre-specified stratification factors, the Company \u201ccannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa.\u201d\n<\/p>\n

\nOn this news, the Company\u2019s share price declined by $14.90 per share, or approximately 43%, to close at $19.74 per share on April 7, 2021.\n<\/p>\n

\nIf you purchased or otherwise acquired FibroGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com<\/a>, telephone at (212) 355-4648, or by filling out this contact form<\/a>. There is no cost or obligation to you.\n<\/p>\n

About Bragar Eagel & Squire, P.C.:<\/b><\/p>\n

\nBragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com<\/a>. Attorney advertising. Prior results do not guarantee similar outcomes.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210408005754\/en\/<\/a><\/span><\/p>\n

\nBragar Eagel & Squire, P.C.
\n
Brandon Walker, Esq.
\n
Melissa Fortunato, Esq.
\n
Marion Passmore, Esq.
\n
(212) 355-4648
\n
investigations@bespc.com
\n<\/a>
www.bespc.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm NEW YORK–(BUSINESS WIRE)– Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our investigation concerns whether FibroGen has violated the federal securities laws and\/or engaged in other unlawful business practices. Click here to participate in the action. On April 6, 2021, FibroGen issued a statement \u201cprovid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (\u2018CKD\u2019).\u201d Specifically, the Company stated that the safety … <\/p>\n

Continue reading “FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-474001","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nFIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm NEW YORK–(BUSINESS WIRE)– Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our investigation concerns whether FibroGen has violated the federal securities laws and\/or engaged in other unlawful business practices. Click here to participate in the action. On April 6, 2021, FibroGen issued a statement \u201cprovid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (\u2018CKD\u2019).\u201d Specifically, the Company stated that the safety … Continue reading "FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-09T01:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm\",\"datePublished\":\"2021-04-09T01:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/\"},\"wordCount\":412,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/\",\"name\":\"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-04-09T01:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/","og_locale":"en_US","og_type":"article","og_title":"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm - Market Newsdesk","og_description":"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm NEW YORK–(BUSINESS WIRE)– Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our investigation concerns whether FibroGen has violated the federal securities laws and\/or engaged in other unlawful business practices. Click here to participate in the action. On April 6, 2021, FibroGen issued a statement \u201cprovid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease (\u2018CKD\u2019).\u201d Specifically, the Company stated that the safety … Continue reading \"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-09T01:03:21+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm","datePublished":"2021-04-09T01:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/"},"wordCount":412,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/","name":"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-04-09T01:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210408005754r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fibrogen-alert-bragar-eagel-squire-p-c-is-investigating-fibrogen-inc-on-behalf-of-fibrogen-stockholders-and-encourages-investors-to-contact-the-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=474001"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/474001\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=474001"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=474001"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=474001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}